KQ-2003 / Novatim Immune Therap - LARVOL DELTA

Novatim and ERIGEN Ink Licensing Pact for Dual-Target CAR-T Therapy KQ-2003 (flcube.com) - "Novatim Immune Therapeutics...announced a strategic cooperation with US-based biopharmaceutical company ERIGEN LLC. The partnership involves an exclusive overseas licensing agreement for Novatim’s self-developed KQ-2003, the world’s first parallel-enhanced dual-target CAR-T cell therapy targeting BCMA/CD19. This collaboration grants ERIGEN exclusive rights to develop, register, and commercialize the product globally, excluding Greater China, India, Turkey, and Russia....Under the agreement, ERIGEN will have exclusive rights to develop 'off-the-shelf CAR-T cell therapies' using the key patent structures and sequences of KQ-2003. Novatim retains complete rights to the off-the-shelf product within Greater China, setting the stage for future joint development and regional commercialization. Novatim will receive an initial milestone payment of $15 million and is eligible for up to $1.32 billion in development, registration, and commercialization milestones."

Licensing / partnership • Multiple Myeloma

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Rare Diseases

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

CAR T-Cell Therapy • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology